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Circumventing Gemcitabine resistance in pancreatic cancer using drug 
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ABSTRACT 
Gemcitabine is the first line treatment of pancreatic cancer, a treatment that is relying on the expression of 
human Equilibrative Nucleoside Transporter 1 for cellular uptake. Combined with its short blood half-life and 
intracellular activation steps, Gemcitabine treatment has many limitations. In this project we tried to circumvent 
the need for cellular uptake as one step towards increasing the efficiency of Gemcitabine treatment. A liposomal 
drug delivery system was tested in vitro combined with chemically blocking the uptake route. Because of 
inconclusive results, the liposomal drug delivery system could not be fully evaluated.  
 
 
 
List of abbreviations: DP – Dipyridamole; DZ – Dilazep; FBS – 
Fetal Bovine Serum; Gem – Gemcitabine; PC – Pancreatic cancer 
 
 
 
 
INTRODUCTION 
 
Pancreatic cancer (PC) is one of the most lethal 
cancer forms. Although it represents only 6% of all 
cancer deaths in the US, only 5 % of all patients 
with PC survive for more than 5 years. 
1
  The low 
survival rates can partly be explained by the high 
degree of resistance the tumor cells acquire and by 
the tumor environment, characterized by low 
vascularization and dense stroma, leading to a poor 
distribution of drugs to the cancer cells. 
2 
The 
stroma consists of various cell types, including 
endothelial cells, immune cells and fibroblasts. 
Evidence suggests that the stromal compartment 
together with the epithelium increases the 
aggressiveness of PC. PC cells distribute molecules 
stimulating the stroma, and the stroma in turn 
releases substances stimulating tumor growth. 
3 
     Most often, patients diagnosed with PC are over 
40 years old, and the median age of diagnosis is 71 
years of age. PC is more common in developed 
countries and is the eighth leading cause of death 
from cancer in men, while it is the ninth leading 
cause of death from cancer in women. The risk 
factors associated with PC are tied to smoking, 
obesity and long-term diabetes. 
4 
     PC is characterized by a lack of symptoms in 
early stages, making it difficult to diagnose in the 
early onset of the disease. Surgical options are often 
limited, 
5, 6
 and only 20% of patients diagnosed with 
PC are eligible for surgical removal of the tumor. 
2, 
7
 In cases where surgery is not an option, other 
possible treatments consist of chemotherapy, 
radiation therapy or a combination of these. 
7
 
     Gemcitabine (Gem), a cytidine analog, is 
commonly used as a standard treatment in patients 
with PC both in palliative and preoperative settings. 
2
 Inside the cells, Gem is phosphorylated to yield 
the active substance prior to incorporation into the 
DNA chain during DNA replication, forcing the 
cell into apoptosis by a process called “masked 
chain termination”. 2, 8 
     The process of masked chain termination can be 
seen in Figure 1. The activated Gem is incorporated 
into the replicating DNA strand by DNA 
polymerase. Afterwards, a nucleotide is inserted, 
camouflaging Gem and preventing removal by 
DNA repair systems. Addition of a second 
nucleotide is now stopped, and chain elongation 
cannot continue. This forces the cell into apoptosis. 
2 
     Even though Gem is the standard treatment for 
PC, it has its limitations. One of the challenges 
regarding Gem-based treatment is the fact that Gem 
is a prodrug in its administered form and needs to 
undergo a series of phosphorylation steps to yield 
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Figure 1. The mechanism of masked chain termination 
First, the activated metabolite of Gem is incorporated into the replicating DNA chain. This is followed by incorporation of a 
nucleotide, masking Gem. This prevents removal of Gem by DNA repair systems. The incorporation of Gem also inhibits further 
incorporation of nucleotides, terminating chain elongation and forcing the cell into apoptosis.  
the active substance. Intracellular resistance 
mechanisms can turn Gem into an inactive form, 
making it unable to exert its cytotoxic properties. 
Of the total amount of Gem administered, 77 % is 
excreted in its inactive metabolite or administered 
form trough renal excretion within 24 hours after 
administration. This creates the need to administer 
higher doses to reach desired effects. 
2, 9, 10
 
     Moreover, Gem has a short blood half-life (t1/2 
between 15 
11
 and 90 min 
12
) and is rapidly 
converted to its inactive form in the plasma. Due to 
this short half-life, there is a need for frequent 
administration. 
11
 High dose in combination with 
frequent administrations give rise to more severe 
side effects. 
2, 9, 10
 Another challenge regarding 
Gem-based chemotherapy is, as previously 
mentioned, the low vascularization in the tumor, 
making it more difficult for Gem to reach the tumor 
cells. 
2
 This is not due to Gem but rather the nature 
of the tumor. However, in combination with the 
aforementioned limitations, this affects the efficacy 
of the treatment. 
     Another reason of concern when using Gem is 
its need for active cellular uptake by hENT1. 
2
 Gem 
is a hydrophilic drug, making diffusion across the 
cell membrane a slow process. Transport across the 
cell membrane is mediated by membrane 
transporters, where hENT1 is the major transporter 
for Gem. 
13
 The expression of hENT1 has been 
linked to the prognosis for PC patients treated with 
Gem, where a high expression of hENT1 is 
associated with a more optimistic prognosis than 
for PC patients with low hENT1-expression. 
[7]
 An 
earlier study on hENT1 as a biomarker studied 
tissue samples from patients with advanced 
pancreatic cancer treated with Gem. This study 
showed that patients with high hENT1 expression 
had a longer survival.
 8 
     hENT1 is a 50 kDa protein with 11 predicted 
trans-membrane domains 
14, 15
 and is responsible for 
uptake of nucleosides from the surrounding 
environment. 
14-16
 In previous studies, hENT1 has 
shown sensitivity towards the blocking effect of 
Dilazep (DZ), Dipyridamole (DP) and 6-S-[(4-
Nitrophenyl)methyl]-6-thioinosine (NBMPR). 
14-16
 
Functional studies of the protein has indicated that 
transmembrane domain 3-6 have great significance 
in inhibitor interactions, 
14 
as well as substrate 
binding. 
15
 
     Equilibrative Nucleoside Transporters (ENT) 
have been found in most cell types throughout the 
body 
14
 and have been divided into two subgroups: 
ENT1 and ENT2. These subgroups are classified 
depending on their sensitivity towards inhibition by 
NBMPR. hENT1 show sensitivity to NBMPR at 
low concentrations, and is therefore classified as 
equilibrative sensitive (es), whereas hENT2 shows 
low sensitivity and is therefore classified as 
equilibrative insensitive (ei). 
14, 17, 18
  
     Since the uptake of Gem is mainly dependent on 
the expression of hENT1, alternative uptake routes 
for the drug are needed to improve prognosis for 
PC patients with low hENT1 expression. In our 
group, we have been using liposomes as a drug 
delivery system in an attempt to circumvent the 
need for active cellular uptake of Gem, thereby 
decreasing the importance of hENT1 expression.    
     Liposomes are artificial vesicles consisting of at 
least one phospholipid bilayer. 
19
 The lipid bilayer 
of the liposome surrounds an aqueous interior, 
where hydrophilic drugs can be encapsulated. 
Hydrophobic drugs can be encapsulated in the 
phospholipid bilayer. Liposomal drug delivery can 
occur by the liposome fusing with the cell 
membrane of another cell, thereby releasing its 
contents in the intracellular compartment. It can 
also occur by endocytosis, where the liposome is 
internalized by the cell via endocytosis, followed by 
the release of the drugs encapsulated in the 
liposome. 
20 
     Initially, two cell lines were chosen for the 
experiment. The cell lines were human PC cell lines, 
chosen based on their expression of hENT1. Capan-
1, a cell line with epithelial morphology was 
3 
 
derived from a liver metastasis in a 40 year old 
male, 
21
 has been shown to have high hENT1-
expression.
 22
 PANC-1 is an epithelial cell line 
derived from the pancreatic duct of a 56 year old 
male, 
23
 and has been confirmed to have low 
hENT1 expression. 
22 
However, as can be seen in 
Figures 1 and 2, Appendix 2 PANC-1 show low 
inhibition of cell viability for the controls treated 
with only Gem. PANC-1 is known to display high 
resistance towards Gem due to its many resistance 
mechanisms, which reduces its sensitivity towards 
Gem. 
24
 This resistance is again proven by our 
results. Since PANC-1 showed lack of response 
towards Gem, the experiments on this cell line were 
discontinued and experiments were conducted on 
BxPC-3 instead. This epithelial human pancreatic 
cancer cell line is more sensitive to Gem than 
PANC-1 
24
, but has similar hENT1 expression. 
25 
     The aim of this study was to see if the uptake of 
Gem could, through a liposomal drug delivery 
system, circumvent the need of active cellular 
uptake. In order to prove this theory, the uptake 
route of Gem (hENT1) was inhibited to simulate a 
low-hENT1 expression environment. From this 
low-expression scenario, we would try to 
circumvent this lack of uptake using liposomes as a 
drug delivery system.  
MATERIAL AND METHODS 
     Cell culture Capan-1 was bought from ATCC 
(LGC, Manassas, VA, USA) and kept in Iscove’s 
modified Dulbecco’s medium (Gibco, Life 
Technologies, Grand Island, NY, USA) with 20% 
fetal bovine serum (FBS, Gibco, Life Technologies). 
800 000 cells were seeded in one T75 flask and the 
cells were used between passages 25 and 40. BxPC-
3 was obtained from ATCC and kept in Roswell 
Park Memorial Institute 1640-Glutamax Medium 
(Gibco, Life Technologies) with 10 % FBS. 
300 000 BxPC-3 cells were seeded per T75 flask 
and the cells were used between passages 23 and 38. 
PANC-1, was obtained from ATCC and was grown 
in Dulbecco’s Modified Eagle Medium (Gibco, 
Life Technologies) supplemented with 10% FBS. 
300 000 PANC-1 cells were grown in one T75 flask 
and used for experiments between passage 3-10.  
     The media for all cell lines were supplemented 
with 100 U/ml penicillin and 100 µg/ml 
streptomycin (Gibco, Life Technologies). Cells 
were grown in T75 flasks in a 5% CO2, 37
o
C 
humidified environment. Cell media was changed 
twice a week and the cells were passaged once a 
week.  
     Before passaging, the cells were washed with 
PBS (Gibco, Life Technologies). TrypLE select 
(Thermo Fisher Scientific, Waltham, MA, USA) 
was used to detach the cells (5 min for PANC-1 and 
BxPC-3, and 10 min for Capan-1, respectively) 
before they were collected and centrifuged at 1400 
rpm for 5 min. After dissolving the pellet in cell 
culture medium, cell concentration was determined 
using a Bürker chamber and 0.06 % Tryphan blue.        
     Expression of hENT1 Whole cell lysates for 
Western Blot were obtained by dissolving 
approximately 1.2 million cells in 1 ml of lysis 
buffer supplemented with Phosphatase inhibitor and 
Protease inhibitor (Thermo Fischer Scientific). The 
samples were incubated on ice for 10 minutes 
before they were frozen in aliquots.  
     Protein determination was carried out using 
NanoDrop 2000c. Whole cell lysate corresponding 
to 2.5 and 5 µg protein was diluted 1:1 with 
Laemmli buffer 2x (S3401, Sigma-Aldrich, St. 
Louis, MO, USA) and boiled for 5 min before they 
were placed in the gel. Samples were run on two 
different gels, BioRad 4-15 % Mini-PROTEAN
® 
TGX™ Precast Protein Gel (4561086, BioRad) for 
detection of 5-200 kDa proteins and BioRad Mini-
PROTEAN
® Any kD™ Precast Protein Gel 
(4569033, BioRad) for detection of 10-100 kDa 
proteins. BioRad Trans-Blot Turbo Transfer System 
(1704155, BioRad) was used for transfer onto a 
nitrocellulose membrane (1704158, BioRad). 
Membranes were blocked in TBST/5 % milk 
powder (Sigma-Aldrich) for 2 hours in room 
temperature on a shaker, followed by 3 washes with 
TBST of 15 minutes each. The anti-hENT1-
monoclonal antibody SP120 (SAB5500117, Sigma-
Aldrich) was diluted 1:1000 in TBST/5% milk and 
mouse-anti-GAPDH (MAB374, Millipore, Billerica, 
MA, USA), used for housekeeping protein, was 
diluted 1:2000, also in TBST/5% milk. Membranes 
were incubated with the appropriate antibody on a 
shaker in 4
o
C overnight. 
     After incubation with antibodies, the membranes 
were washed with TBST/5 % milk powder twice 
for 15 minutes, followed by a single wash with 
TBST, 15 min. Goat-anti-rabbit HRP diluted 
1:2000 (A0545, Sigma-Aldrich) was used against 
SP120 and Goat-anti-mouse HRP (A4416, Sigma-
Aldrich) 1:10000 for housekeeping protein. Both 
antibodies were diluted in TBST/5% milk. 
Membranes were incubated for 1 hour in 4
o
C. The 
membranes were washed three times in TBST for 
4 
 
15 minutes each, before detection using 
SuperSignal West Femto Maximum Sensivitity 
Substrate (34095, Thermo Fischer Scientific) per 
manufacturer’s instructions. Results were obtained 
using LiCor chemiluminescence Detection System.  
     Immunofluorescence For immuno-fluorescent 
staining, cells were seeded in 8-well chamber slides 
at a concentration of 15 000 cells/chamber. The 
cells were seeded in 200 L medium and were left 
in the incubator for 72 hours before staining. After 
72 hours, the chambers were rinsed with ice cold 
PBS before they were fixed in Paraformaldehyde (2% 
in PBS/0.2 % Triton x-100) on ice for 20 minutes. 
The cells were rinsed twice with ice cold PBS 
before blocking in block solution, containing 100 
L Donkey serum (Sigma Aldrich) and 1900 L 
PBS/0.2 % Triton x-100, on ice for 30 minutes. 
Slides were washed twice with ice cold PBS before 
addition of primary antibody (SP120, 1:50, diluted 
in PBS/0.2% Triton x-100) and incubated for 1 
hour in room temperature. This was followed by 
secondary antibody, donkey-anti-rabbit FITC 
(A21206, Thermo Fischer Scientific), after washing 
the chambers twice with PBS, and incubated for 50 
minutes in darkness. Chambers were rinsed 3 times 
with PBS and stained with DAPI (Thermo Fischer 
Scientific) for 5 minutes before slides were rinsed 
with PBS and mounted. The stainings were carried 
out twice in duplicates.  
     Co-treatment Cells were seeded in 96-well 
plates with a concentration of 5 000 cells/well for 
24 hours to allow cell adhesion before treatment 
with Gem (Sigma-Aldrich) and inhibitor. Stock 
solutions of NBMPR and DZ were prepared. 
NBMPR was dissolved in DMSO and DZ in dH20, 
with a final concentration of 100 mM. The stock 
solution was diluted to the desired concentrations 
tested in the experiment - 1, 50, 10 and 100 nM for 
NBMPR (Sigma-Aldrich) and  1, 10, 20 and 50 nM 
for DZ (Sigma-Aldrich). These concentrations were 
tested against 3 concentrations of Gem (Sigma-
Aldrich, 10, 50 and 100 M). All combinations 
were tested in triplicates (n=3). After 24 hour 
incubation, 100 L Gem/inhibitor solution was 
added after removal of the medium by turning the 
plate upside down on paper tissues. Plates were 
incubated 24 or 48 hours before a cell viability 
measurement was done.  
     Pre-treatment Cells were seeded in 96-well 
plates with a concentration of 3 000 cells/well for 
72 hours before treatment with inhibitor, followed 
by a treatment with both inhibitor and Gem. The 
concentrations for NBMPR and DZ were as 
previously described. A series of concentrations 
within micro molar range was also tested (0.5, 1, 5 
and 15 µM). These concentrations were used for the 
treatments with DP (Sigma Aldrich). A stock 
solution was prepared, where DP was dissolved in 
DMSO to a concentration of 100 mM. This stock 
solution was then diluted to the desired 
concentrations. The Gem concentrations tested 
were the same as in Co-treatment described 
previously. After 72-hour incubation, 100 L 
inhibitor diluted in growth medium was added after 
removal of the medium by turning the plate upside 
down on paper tissues. Plates were incubated for 24 
hours before the wells were emptied as described 
previously. After emptying the plates, 100 L 
Gem/inhibitor (n=3) were added to the wells and 
incubated for 24 or 48 hours. After 24 or 48 hours, 
a cell viability measurement was done.  
     Liposome preparation Liposomes of 
DPPC:Chol:DSPE-mPEG2000  (80:20:5) molar 
ratios were prepared by the thin lipid hydration 
technique. 
26
 Briefly, phospholipids were weighed 
and dissolved in a round bottom flask using a (3:1 
v/v) mixture of chloroform: methanol. In order to 
form a thin lipid film, organic solvents were 
removed under rotation and reduced pressure at 
60ºC using a Büchi Rotavapor for 1 hour. Lipid 
films were further dried overnight in a Labconco 
Freezone Plus 6 lyophilizer (Labconco Corporation, 
Kansas City, MO, USA) in order to remove all 
traces of organic solvents. After drying, lipid films 
were hydrated with either Hepes Buffered Saline 
(HBS, pH 7.4) or a Gem solution under rotation at 
60ºC for 1 hour and further vortexed until all lipid 
film dissolved. The multilamellar suspension was 
serially extruded 11 times through a 200 nm and 
100 nm stacked pair of polycarbonate filters, each, 
to obtain a unilamellar suspension of small 
liposomal vesicles. Non-encapsulated Gem was 
removed from solution by gel chromatography 
using a Sephadex G25 column (GE Healthcare Life 
Sciences AB, Uppsala, Sweden), columns were 
equilibrated with HBS. Liposomes were prepared 
by the supervisor for use of the student in the 
aforementioned experiments. 
     GemLip Treatment 3 000 cells/well were seeded 
in 96-well plates for 72 hours before pre-treatment. 
After the 72-hour incubation time, the cell culture 
medium was removed by turning the plate upside 
down on paper tissues. The plates were pre-treated 
with the appropriate DP-concentration (0.5, 1, 5 or 
5 
 
15 M) for 24 hours before GemLip treatment and 
control treatments.  
     After 24-hour Pre-treatment incubation, the 
medium was removed as described previously. The 
cells were treated with a combination of DP and 
GemLip, where all DP concentrations were tested 
against all GemLip concentrations. GemLip, Gem, 
Lip and DP were tested alone, and a combination of 
DP/Gem and DP/Lip were tested. 100 L treatment 
solution was added to each well and incubated for 
24 or 48 hours. After 24 or 48 hours, a cell viability 
measurement was done. 
Cell viability measurement Cell viability 
measurement was performed with WST-1 (Sigma-
Aldrich). WST-1 was added to the wells followed 
by 4 hour incubation. After the 4 hour incubation 
time, the absorbance was read at =450 nm for cell 
viability and =660 nm for background. 
     Statistical analysis Co-Treatment, Pre-
Treatment and GemLip-treatment assays are 
presented as means in per cent ± standard deviation 
in per cent. Statistical analysis was performed with 
Ordinary one-way ANOVA by use of GraphPad 
Prism 7.  
 
RESULTS 
     Western blot In order to demonstrate the 
presence of hENT1, a Western blot was performed. 
As can be seen in Figure 2, Western Blot showed 
traces of hENT1 in both Capan-1 and BxPC-3, even 
though the bands are weak. Samples were loaded 
onto the gel with two different protein amounts and 
as can be seen in the Figure, as the bands are 
weaker with decreasing protein amount. Compared 
to the housekeeping protein (GAPDH), the hENT1 
expression is lower. 
     Immunofluorescence As a complement to 
Western blot in the process of demonstrating the 
presence of hENT1, immunofluorescent staining 
targeting hENT1 was performed. Capan-1 and 
BxPC-3 were seeded and stained as described in the 
method section and the fluorescent stainings are 
shown in Figure 3. Negative control for Capan-1 is 
displayed in A, showing no fluorescence. Capan-1 
did show staining on some of the cells, but not on 
all. The results indicate hENT1 being present since 
some fluorescence is visible, even though 
fluorescence cannot be seen around all cells. The 
same goes for BxPC-3, which also shows 
fluorescent staining for hENT1 on some of the cells. 
The negative control for BxPC-3 does not show the 
green fluorescent staining for hENT1.   
    Pre-Treatment In order to obtain an optimal 
blocking protocol, cells were treated with inhibitor 
for 24 hours before addition of inhibitor and Gem, 
as previously described in the Pre-Treatment 
section. As shown in Figure 4, BxPC-3 cells treated 
with a combination of DP and Gem display a 
inhibition of Gem uptake after 48 hours than cells 
treated with Gem only. This is true for all cells 
independent of the Gem concentration they were 
treated with (10, 50 or 100 µM). According to these 
results, a higher DP concentration correlates with 
higher inhibition of Gem, indicated by higher cell 
Figure 2. Western blot with hENT1 and GAPDH in BxPC-3 and Capan-1 cell lines 
Whole cell lysates corresponding to 2.5 or 5 ug protein were run on the gel before transferred onto a 
nitrocellulose membrane. The membranes were blocked before stained with primary antibody (SP120 for 
hENT1, diluted 1:1000 and mouse-anti-GAPDH for housekeeping gene, diluted 1:2000) and secondary antibody 
(Goat-anti-mouse HRP for detection of hENT1, diluted 1:2000 and goat-anti-mouse HRP for detection of 
housekeeping gene, diluted 1:10000). SuperSignal West Femto Maximum Sensivitity Substrate was used 
according to manufacturer’s instructions for detection. A. BxPC-3, 5 µg protein B. BxPC-3, 2,5 µg protein C. 
Capan-1, 5,0 µg protein D. Capan-1, 2,5 µg protein. The results show a weak band for hENT1 compared to the 
band of GAPDH. Despite the band for hENT1 being weak, it still shows the presence of hENT1. hENT1 is 
located in the upper bands and housekeeping gene (GAPDH) is located in the lower bands. 
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viability. This inhibition of Gem uptake cannot be 
seen after 24 hours.  
     Capan-1 cells (Figure 5) were treated as 
described previously in the Pre-treatment section. 
The cells treated with a combination of DP and 
Gem do not show an inhibition of Gem uptake 
compared to the controls treated with only Gem. on 
the contrary, after 48 hours, the cell viability for 
cells treated with only Gem is higher than for cells 
treated with DP and Gem, indicating a still 
functioning Gem uptake, namely an unsuccessful 
blocking of hENT1. 
     GemLip-Treatment As shown in Figure 6, the 
inhibition of Gem seen in Figure 4 for BxPC-3 cells 
is not present here. This is indicated by the cell 
viability for the cells treated with only Gem was 
similar to the cell viability of the cells treated with 
DP and Gem. This strongly suggests that the 
inhibition of Gem uptake seen in the Pre-
Treatments are not present here. Furthermore, 
Figure 6 also indicates either a successful Gem 
delivery to the cells by the liposomes or a leakage 
of Gem from the liposomes to the surrounding 
environment. This is indicated by the control for 
free Gem being similar to the control for liposomal 
Gem (GemLip). The cells treated with a 
combination of DP and GemLip as well as the cells 
treated with only GemLip show similar cell 
viability as  
the cells treated with only Gem.  
     Similar to what was observed with experiments 
using BxPC-3, no inhibition of hENT1 was seen 
using Capan-1, Figure 7. These results correlate 
with the results in Figure 5 where there was a poor 
blocking of hENT1. The cell viability for the cells 
treated with a combination of DP and Gem show 
similar cell viability as the cells treated with Gem 
only, which does not indicate inhibition of Gem 
uptake as a consequence of blocking hENT1. 
Furthermore, the results here just like the results in 
Figure 7 indicate either a successful Gem delivery 
by the liposomes, or a leakage of Gem from the 
liposomes to the cell media. This is again indicated 
by the fact that the cell viability for cells treated   
Figure 3. hENT-1 immunoreactivity in Capan-1 and BxPC-3 cells 
Capan-1 cells and BxPC-3 cells were grown for 72 hours before fixation in in 2% paraformaldehyde/0.2% Triton-X 
100. Cells were stained with (B, D) or without (A, C) the SP120 antibody directed towards hENT1 (Green staining, 
diluted 1:50). All cells were stained with DAPI (A-D, blue) for detection of the cell nuclei. Control cells (A, C) were not 
stained with SP120 but rather with secondary antibody and DAPI only. The scale bars represent 50 µm. The figure 
shows representative results (n = 4). Capan-1 and BxPC-3 negative controls (A, C) does not show green fluorescence 
for hENT1, whereas the staining using the SP120 antibody (B, D) show green fluorescence.  
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Figure 4. Pre-Treatment with Dipyridamole (DP) on the BxPC-3 cell line 
BxPC-3 cells were grown for 72 hours followed by a 24-hour treatment with DP. This was followed by a 24- or 48-hour co-
treatment with DP and Gemcitabine. The results displayed in the figure show decreased cell viability after 48 hours (B) for 
cells treated with DP. After 24 hours, an increase in cell viability for cells treated with DP is not seen.  From left to right: 
Gem (black bar), 0.5 µM DP + Gem, 1 µM DP + Gem, 5 µM DP + Gem and 15 µM DP + Gem. The first group of bars 
represents cells treated with 10 µM Gem, the second 50 µM Gem and the third 100 µM Gem. 24:24 – 24 hour Pre-Treatment 
followed by a 24 hour Co-treatment. 24:48 – 24 hour Pre-Treatment followed by a 48 hour Co-Treatment. For all conditions, 
data is expressed as mean cell viability in percent of control ± standard deviation in per cent, n=3 * = P ≤ 0.05, ** = ≤ 0.01, 
*** = P ≤ 0.001, **** = ≤ 0.0001  
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Figure 5. Pre-Treatment with Dipyridamole (DP) on Capan-1 cell-line 
Capan-1 cells were grown for 72 hours followed by a 24-hour treatment with DP. This was followed by a 24- or 
48-hour co-treatment with DP and Gemcitabine. These results from the treatments using DP on Capan-1 cells do 
not show decreasing cell viability for cells treated with DP, both after 24 and 48 hours.  From left to right: Gem 
(black bar), 0, 5 µM DP + Gem, 1 µM DP + Gem, 5 µM DP + Gem and 15 µM DP + Gem. The first group of 
bars represents cells treated with 10 µM Gem, the second 50 µM Gem and the third 100 µM Gem. 24:24 – 24 
hour Pre-Treatment followed by a 24 hour Co-treatment. 24:48 – 24 hour Pre-Treatment followed by a 48 hour 
Co-Treatment. For all conditions, data is expressed as mean cell viability in percent of control ± standard 
deviation in per cent, n=3. * = P ≤ 0.05, ** = ≤ 0.01, *** = P ≤ 0.001, **** = ≤ 0.0001 
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Figure 6. Pre-Treatment with Dipyridamole (DP) followed by a 24- or 48-hour Co-Treatment with 
GemLip using the BxPC-3 cell line 
BxPC-3 cells were grown for 72 hours before a 24-hour treatment with DP. This was followed by a 24- or 48-
hour treatment with either free Gemcitabine of liposomal Gemcitabine before cell viability was measured. When 
comparing cells treated with DP and Gem with cells treated only with Gem, the cell viability does not differ 
between the treatments. Also, when comparing the cell viability presented by the cells treated with a combination 
of DP and GemLip with the cells treated with only GemLip, they show similar cell viability. The cell viability for 
DP/Gem treatments does not differ from DP/GemLip treatments. From left to right: Gem, GemLip, 5 µM 
DP/Gem, 15 µM DP/Gem, 5 µM DP/GemLip, 15 µM DP/GemLip. The first group of bars represents cells treated 
with 10 µM Gem, the second 50 µM Gem and the third 100 µM Gem. 24:24 – 24 hour Pre-Treatment followed 
by a 24 hour Co-treatment. 24:48 – 24 hour Pre-Treatment followed by a 48 hour Co-Treatment. For all 
conditions, data is expressed as mean cell viability in percent of control ± standard deviation in per cent, n=3. * = 
P ≤ 0.05, ** = ≤ 0.01, *** = P ≤ 0.001, **** = ≤ 0.0001 
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Figure 7. Pre-Treatment with Dipyridamole (DP) followed by a 24- or 48-hour Co-Treatment using Capan-1 
cell line.  
Capan-1 cells were grown for 72 hours before a 24-hour treatment with DP. This was followed by a 24- or 48-hour 
treatment with either free Gemcitabine of liposomal Gemcitabine before cell viability was measured. When 
comparing cells treated with DP and Gem with cells treated only with Gem, the cell viability does not differ 
between the treatments. Also, if one compares the cell viability presented by the cells treated with a combination of 
DP and GemLip with the cells treated with only GemLip, they show similar cell viability. The cell viability for 
DP/Gem treatments does not differ from DP/GemLip treatments. From left to right: Gem, GemLip, 5 µM DP/Gem, 
15 µM DP/Gem, 5 µM DP/GemLip, 15 µM DP/GemLip. The first group of bars represents cells treated with 10 
µM Gem, the second 50 µM Gem and the third 100 µM Gem. 24:24 – 24 hour Pre-Treatment followed by a 24 
hour Co-treatment. 24:48 – 24 hour Pre-Treatment followed by a 48 hour Co-Treatment. For all conditions, data is 
expressed as mean cell viability in percent of control ± standard deviation in per cent, n=3. * = P ≤ 0.05, ** = ≤ 
0.01, *** = P ≤ 0.001, **** = ≤ 0.0001 
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with only GemLip is similar to the cell viability for 
cells treated with only Gem. 
 
DISCUSSION 
     The transmembrane transporter hENT1 is 
important for Gem sensitivity as it has been 
identified as the main uptake route of Gem. 
2, 8 
 The 
expression of hENT1 is particularly important as it 
has been correlated to prognosis and helps predict 
patient response to Gem treatment. 
9
 As such, 
finding a way to circumvent the need for active 
cellular Gem uptake by hENT1 is a step towards a 
less transport-dependent uptake and a more 
efficient treatment.  
     hENT1 inhibition To create a model of low 
hENT1-expression, the function of hENT1 needed 
to be inhibited. This was possible in two ways; 
pharmacological inhibition of hENT1 or by siRNA 
gene silencing. It has previously been reported that 
NBMPR, DZ and DP inhibit hENT1 at nanomolar 
concentrations. 
27
 Based on this, NBMPR and DZ 
were initially chosen for the pharmacological 
inhibition experiments. NBMPR in particular was 
chosen due to its role in the definition of es and ei 
nucleoside transporters. 
14, 17, 18
 NBMPR has been 
reported to inhibit transport mediated by hENT1 at 
low concentrations (Inhibitory constant, Ki = 10 
nM). 
14
 DZ has also been reported to inhibit the 
nucleoside transport trough hENT1 at low 
concentrations (Ki = 19 nM). 
27
 Therefore, NBMPR 
and DZ were chosen for the experiments.  
     The Ki values previously mentioned for both DZ 
and NBMPR were used as a starting point for the 
concentrations which were later used in the 
experiments. However, as can be seen in Appendix 
2, DZ and NBMPR did not reach satisfactory 
inhibition of hENT1. The concentrations were 
raised from nanomolar to micromolar to see if 
results could be obtained by using higher 
concentrations.  As these results too were 
inconclusive, this lead to the decision to use DP 
instead of NBMPR and DZ. 
     DP is an ENT-inhibitor, just as DZ and NBMPR, 
and it has been reported to inhibit hENT1 (Ki = 48 
nM). 
27
 The reported Ki for DZ is lower than the Ki 
reported for DP, and therefore DZ was initially 
chosen over DP. The micromolar concentrations 
previously used for DZ and NBMPR were used for 
DP as well, and as can be seen in Figure 5 and 6, 
this gave an inhibition of approximately 20% 
compared to the untreated cells, in the highest 
inhibitor concentrations.  
     For both NBMPR and DP, DMSO was used as a 
solvent. It is known that DMSO is toxic to cells by 
interaction with the cell membrane and the cells’ 
metabolism, causing cell damage. 
28 
However, the 
stock solution prepared with DMSP was of the 
highest possible concentration to allow as much 
dilution of DMSO as possible. To achieve the 
desired concentration, this means a 100x dilution 
was needed to reach a concentration of 100 μM 
before further dilution to reach the concentrations 
used in the treatments. This resulted in the DMSO 
concentration being lower than 0.1% and its 
possible cytotoxic effect was not taken into 
consideration. 
     It has been reported that siRNA gene   silencing 
indeed does reduce the amount of hENT1 expressed. 
29
 However, there is no mention regarding the 
degree of silencing, making it difficult to predict 
the amount of silencing that can theoretically be 
achieved. Because of this insufficient information, 
and the complex protocols for gene silencing, we 
chose to first use chemical inhibition ahead of 
siRNA gene silencing.      
     hENT1 expression Western blot was made to 
demonstrate the presence of hENT1, just as the 
immunofluorescence. Western Blot shows very 
weak bands even for Capan-1 which is known to 
have a high hENT1 expression, 
22
 as mentioned in 
the introduction. However, the sample run was a 
whole cell lysate and no purification steps were 
conducted before electrophoresis. This means that 
the amount of protein measured in the sample, and 
loaded on to the gel, were all the expressed proteins 
and not only hENT1. As a consequence, of the total 
amount of proteins loaded on to the gel only a 
smaller fraction of the proteins were hENT1, which 
could explain why the bands on the gel are very 
weak. The reason for running a whole cell lysate 
instead of purifying the membrane bound proteins 
is because of the process being both a complicated 
and a time-consuming task. What could have been 
done to increase the protein concentration in the 
cell lysate was to increase the amount of cells per 
ml of lysis buffer.  
     One cannot exclude the antibody function as a 
reason for the weak bands displayed in the western 
blot. The only type of control used for the western 
blot was GAPDH, which means that the antibody 
targeting hENT1 was not tested against a positive 
control consisting of hENT1. What could have been 
done was to buy hENT1 and load the protein in one 
well on the gel to test the antibody against a 
positive control of the same protein that was 
12 
 
targeted. Therefore, one could see if the weak bands 
were because of a low amount of hENT1 or 
because of the function of the antibody.  
     Immunofluorescence was performed to detect 
the presence of hENT1. hENT1 was stained using 
SP120, a rabbit-anti-hENT1 monoclonal antibody. 
30
 Previous studies have used SP120 for 
immunohistochemistry with 1:50 
30, 31
 and with 
1:100 dilutions. 
31
 With the information previously 
mentioned, we chose to use one antibody dilution, 
1:50. As Figure 3 shows, hENT1 is visible through 
its green fluorescence, and cell nuclei are stained 
blue. Figure 3 demonstrates that for both BxPC-3 
and Capan-1, there is staining for hENT1 but not on 
all cells. Some cells only display the blue color for 
cell nuclei. Previous reports have used the SP120 
anti-hENT1 antibody for immunohistochemistry 
and not immunofluorescence, which can be part of 
the explanation as to why the staining is only partial.  
     hENT1 inhibition experiments Initially, a Co-
Treatment was performed. In this Co-Treatment, 
inhibitor and Gem was mixed and added to the cells 
simultaneously. The cell viability was measured 
after 24 or 48 hours. As can be seen in Figures 1-4, 
Appendix 2 there is no evident difference between 
the cells treated with Gem and the cells treated with 
a combination of the inhibitor and Gem. These 
results led to the suspicion that there was not 
enough time for the inhibitor to bind to hENT1 and 
limit Gem uptake before a toxic amount of Gem 
was taken up. 
     To give the inhibitor some time to bind to 
hENT1 before addition of Gem in combination with 
the inhibitor, a series of incubation times for a Pre-
Treatment was tested. Figures 5-12, Appendix 2 
show the results from the different incubation times 
for the different inhibitors and cell lines. These 
results are inconclusive but still more promising 
than the Co-Treatment. Since the first two 
inhibitors chosen for the experiment did not work, 
DP was tested in the same Pre-Treatment setting as 
DZ and NBMPR had been. DP was added 24 hours 
prior to the addition of a combination of DP and 
Gem. These results can be viewed in Figures 4 
(BxPC-3) and 5 (Capan-1). The results for BxPC-3 
clearly state that at the highest concentration of DP 
(15µM) the inhibition of cell viability decreases 
from ~55% to ~75% for the two lower Gem 
concentrations, compared to control. 
     Cell culture When cultured, manufacturer’s 
instructions were followed. BxPC-3 were grown in 
medium supplemented with 10% FBS, 
32
 whereas 
Capan-1 was grown in medium supplemented with 
20% FBS. 
21 
FBS is a combination of proteins, 
growth factors, vitamins and other components 
essential for cell growth. 
33
 Therefore, one cannot 
exclude that the differences in FBS concentration in 
the growth medium affected the results. Capan-1 
has twice the amount of FBS compared to BxPC-3, 
and therefore a different environment. The cells 
were also grown in two different growth medium, 
where BxPC-3 were grown in RPMI and Capan-1 
in IMDM. The cells therefore had different 
conditions for growth. The manufacturer's intrigues 
were followed, but this causes a difference between 
how the two cell lines are grown and thus a 
difference between the cells in the experiment.  
     GemLip experiments The results from the 
GemLip experiments are inconclusive. This 
because the inhibition seen in the Pre-Treatment 
was lost during the GemLip treatments. The cells 
treated with a combination of DP and Gem did not 
indicate an inhibited Gem uptake and the blocking 
of hENT1 by DP are not demonstrated in Figures 6 
and 7.  The data from the cells treated with GemLip 
indicates two things; a successful Gem delivery or a 
possible leakage of Gem from the liposomes. When 
comparing the cells treated with only Gem to the 
cells treated with only GemLip, these display 
similar cell viability, indicating a similar inhibition 
of proliferation. No assays determining the leakage 
of Gem from the liposomes were done.  
     Identifying the malfunctioning component in the 
experiment is not feasible based on the data 
available. 12 passages differ between the cell lines 
used for the Pre-Treatment and the results from 
GemLip. GemLip were tested on cells at between 
passages 35 and 40, and Pre-Treatment was 
performed 12 passages earlier. Based on the data 
available, one cannot rule out changes in the cell's 
gene expression, which may have changed the 
amount of hENT1 expressed, or may even have 
altered the protein. Changes in mRNA levels could 
have been analyzed with qRT-PCR, an analysis that 
could have given more insight into what went 
wrong with the GemLip experiments. 
     Because the cells used had high passage number, 
a GemLip treatment was performed on new cells. 
These cells passage number was below 10. The 
results can be seen in Figure 3, Appendix 1 (BxPC-
3) and Figure 5, Appendix 1 
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(Capan-1). The cell viability values for the 
experiments can be seen in Table 3, Appendix 1 
(BxPC-3) and Table 4, Appendix 1 (Capan-1). 
     To exclude inhibitor function as a reason for the 
inconclusive results, an assay evaluating inhibitor 
binding could provide additional details. A binding 
assay, which evaluates the amount of inhibitor 
bound to the cells, could provide information 
regarding the possible change in the amount of 
inhibitor bound to the cells at the time for the Pre-
Treatment and at the time for the GemLip 
treatments. If there was a change in inhibitor 
binding, a binding assay may have provided that 
information. 
     The quality of the inhibitor cannot be excluded 
from the equation. It is possible that the inhibitor 
lost its function partly or completely while stored. 
A stock solution was frozen (-20
o
C) in aliquots, and 
new aliquots were thawed for each experiment. 
Therefore, freeze-thaw cycles can be excluded as a 
reason for this loss of function. However, product 
information sheets mentioning stability for a DP 
solution recommends storing the DP solution in 
aliquots at -20 
o
C for use within a month. 
34  
 
CONCLUSION AND FUTURE 
PERSPECTIVES 
     Based on the results generated by the experiment, 
it is difficult to draw a conclusion. The results 
indicate that GemLip either delivers Gem to the 
cells or that there is leakage of Gem from GemLip. 
One reason cannot be excluded for the benefit of 
another based on the data obtained during the 
course of the project. 
     If GemLip successfully delivers Gem to the cells, 
this Gem delivery does not inhibit proliferation to a 
greater extent than free Gem. Gem is still needed 
for the treatment of PC, a treatment that is 
complicated by the complexity and aggressiveness 
of PC. More research on the subject can provide 
more insight into liposomal Gem and its positive 
effects in the treatment of PC. Optimizing 
chemotherapy treatment in combination with more 
effective screening methods and diagnostic tools is 
a crucial step in prolonging life, to provide better 
quality of life for affected individuals, but is also a 
step in the process of decreasing the mortality rate 
displayed by PC. Finding biomarkers and creating 
an accessible and accurate diagnostic tool for early 
diagnosis is important. However, it is also 
important that the treatment for PC is more 
effective, and therefore further research in drug 
delivery systems is of uttermost importance.  
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Appendix 1 
 
The cells were treated as mentioned in the GemLip-section. Figures 1 and 2 show controls for the GemLip 
experiments shown in the Results section. The results in Figures 1 and 2 show cell viability for cells treated with 
DP, empty liposomes or a combination of these. This was done to see if DP or the liposomes are toxic alone or in 
combination. Figure 1A and 1C show DP-treated cells in comparison to untreated cells and cells that were given 
empty liposomes in comparison to untreated cells. These Figures show that DP and empty liposomes are not 
toxic to BxPC-3 when not given in combination. Figure 2A and 2C show the same results for Capan-1 – DP and 
empty liposomes are not toxic when given separately.  
 
Figure 1B and 1D show cell viability for the cells treated with a combination of DP and empty liposomes. This 
in order to see if the inhibitor and the drug delivery system in itself were toxic to the cells combined. As can be 
seen in the Figure, DP and empty do not display toxicity when combined. The same goes for Capan-1, Figure 2B 
and 2D. Together, Figure 1 and 2 show that DP and empty liposomes are not toxic when given separately or in 
combination with one another. Therefore, the toxicity shown for the cells treated with GemLip has to be 
mediated by Gem only. Supplementary data for these experiments can be seen in Table 1 and 2 for BxPC-3. 
 
Figure 3 show the results from GemLip on new BxPC-3 cells. The results are similar to the results displayed by 
the old cells. Inhibition and GemLip treatments are inconclusive, and the Figure indicated a successful Gem 
delivery, but an unsuccessful hENT1 inhibition by DP. It is again proven, in Figure 4, that DP and empty 
liposomes display no toxicity alone or in combination. 
 
Figure 5 show the results from GemLip-treatments on new Capan-1 cells. These results differ from the results 
displayed by the old Capan-1 cells. The cell viability is significantly lower than previously demonstrated. The 
cells also behaved differently in the cell culturing flask, growing much faster than the old cells did. Figure 6 
show that this increase in toxicity is not influenced by DP or the liposomes, which means that the decreased cell 
viability is a consequence of Gem. No inhibition is displayed by the cells in Figure 5, similar to previous 
experiments. Because of the differences in behavior by the cells, the results are not comparable to the previous 
results on the old Capan-1 cells. Supplementary data can be seen in Table 3 and 4.   
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Figure 1. Controls for the GemLip experiments on old BxPC-3 cells. 
The Figure show controls for the GemLip experiments. A and C display a comparison between untreated cells and cells 
treated with DP and empty Liposomes. A display cell viability after 24 hours and C after 48 hours. B and C show cell 
viability for the combination of DP and empty Liposomes in the different concentrations. These controls were done in order 
to see if the inhibitor and the liposomes were toxic alone or in combination. The figure shows that DP and empty Liposomes 
were not toxic, both alone and in combination.  
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Figure 2. Controls for the GemLip experiments on old Capan-1 cells. 
Shown in the Figure are controls for the GemLip experiments. A and C display a comparison between untreated cells and 
cells treated with DP and empty Liposomes. A do display cell viability after 24 hours and C after 48 hours. B and C show 
cell viability for the combination of DP and empty Liposomes for the different concentrations. These controls were done in 
order to see if the inhibitor and the liposomes were toxic alone or in combination. The figure shows that DP and empty 
Liposomes were not toxic, both alone and in combination.  
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Table 1. The values for the GemLip experiments conducted on old BxPC-3 cells. The values are the 
mean cell viability in per cent ± standard deviation in per cent. 
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Table 2. The values for the GemLip experiments conducted on old Capan-1 cells. The values are the mean 
cell viability in per cent ± standard deviation in per cent. 
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Figure 3. 24 hour Pre-Treatment with DP followed by a 24- (A) or 48-hour (B) co-Treatment with GemLip and DP 
using new cells from the BxPc-3 cell line.  
The results displayed in this set of figures are similar to the previous results displayed by the older cells from the same cell 
line. Overall, the results are inconclusive with inhibition being present at some places and absent at other. The results 
indicate successful Gem delivery by GemLip, since the cell viability for the cells treated with GemLip has decreased.  
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Figure 4. Controls for the GemLip experiments on new BxPC-3 cells. 
Shown in the Figure are controls for the GemLip experiments. A and C display a comparison between control (cells only 
given growth medium) cells and cells treated with DP and empty Liposomes. A display cell viability after 24 hours and C 
after 48 hours. B and C show cell viability for the combination of DP and empty Liposomes for the different concentrations 
after 24 or 48 hours. These controls were done in order to see if the inhibitor and the liposomes were toxic alone or in 
combination. The figure shows that DP and empty Liposomes were not toxic, neither alone or in combination.  
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Figure 5. 24 hour Pre-Treatment with DP followed by a 24- (A) or 48-hour (B) co-Treatment with GemLip and DP 
using new cells from the Capan-1 cell line.  
The results displayed in this set of figures differ from the previous results displayed by the older cells from the same cell line. 
Overall, the results are inconclusive with inhibition being absent. The results indicate successful Gem delivery by GemLip, 
since the cell viability for the cells treated with GemLip has decreased. The cell viability for all cells are substantially lower 
than the cell viability displayed by the old Capan-1 cells.  
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A B 
C D 
Figure 6. Controls for the GemLip experiments on new Capan-1 cells. 
Shown in the Figure are controls for the GemLip experiments. A and C display a comparison between control (cells only 
given growth medium) cells and cells treated with DP and empty Liposomes. A display cell viability after 24 hours and C 
after 48 hours. B and C show cell viability for the combination of DP and empty Liposomes for the different concentrations 
after 24 or 48 hours. These controls were done in order to see if the inhibitor and the liposomes were toxic alone or in 
combination. The figure shows that DP and empty Liposomes were not toxic, neither alone or in combination.  
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Table 3. The values for the GemLip experiments conducted on new BxPC-3 cells. The values are cell viability 
in per cent ± standard deviation in per cent. 
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Table 4. The values for the GemLip experiments conducted on new Capan-1 cells. The values are cell viability in 
per cent ± standard deviation in per cent. 
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Appendix 2 
 
Co-treatment 
 
Cells were treated as mentioned in Material & Methods. All in all, the Co-Treatment shows modest results, with 
lack of inhibition of hENT1. The values for PANC-1 shown in Figure 1 and Figure 2 indicate that no effect from 
Gem is visible after 24 hours. Some effect is observed after 48 hours, but the Figures also indicate the absence of 
inhibition of hENT1, and thereby Gem uptake. The cells treated with Gem do not demonstrate lower cell 
viability than cells treated with a combination of Gem and inhibitor. These inconclusive results indicate a 
malfunctioning inhibition. Important to note, as mentioned in the discussion, is that PANC-1 has resistance 
mechanisms which lower the sensitivity towards Gem. These results may therefore be the result of a 
combination of the resistance to Gem shown by PANC-1, and a lack of effect of the inhibitor in its role of 
inhibiting hENT1.  
  
Cells treated with only Gem show a cell viability >80% after 48 hours. Because of this observed resistance, the 
hypothesis was that the differences between cells treated with the inhibitor and Gem, and control cells treated 
only with Gem would not be large enough to indicate a successful treatment. This because the cell line is not 
affected as much as would be needed to display differences. In other words, cells with functioning uptake 
(hENT1 not inhibited) still have intracellular resistance mechanisms as protection against the function of Gem. 
Therefore, the experiments on PANC-1 were discontinued and BxPC-3 was tried instead.  
 
The results for Capan-1 in the Co-Treatment setting were similar to the results of PANC-1, with the exception 
that the amount of resistance demonstrated by PANC-1 was not demonstrated by Capan-1. The results in Figures 
3 and 4 indicates a non-working inhibition of hENT1, since the cell viability measured for cells treated with only 
Gem is similar to the cell viability measured for the cells treated with a combination of Gem and inhibitor. It also 
indicates the occurrence of Gem uptake, since the cell viability is generally lower after 48 hours than after 24, 
indicating that Gem has an effect on the cells.  
 
Our hypothesis was that the reason for these inconclusive results could be due to the fact that inhibitor and Gem 
were added at the same time. This could mean that there was no time for the inhibitor to elicit its effect before 
Gem uptake occurred, meaning that the inhibition took place after Gem were taken up. From this hypothesis, we 
tried a Pre-Treatment instead, where the cells were treated with inhibitor before the cells were treated with a 
combination of Gem and the inhibitor.   
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Figure 1. Co-Treatment on PANC-1 with DZ. 
The results indicate an unsuccessful inhibition of hENT1 by DZ, since the cell viability for the cells 
with hENT1 inhibited is not higher.  From left to right: Gem (black bar), 1 nM DZ + Gem, 10 nM 
DZ + Gem, 25 nM DZ + Gem and 50 nM DZ + Gem. The first group of bars represents cells treated 
with 10 µM Gem, the second 50 µM Gem and the third 100 µM Gem.  
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Figure 2. Co-Treatment on PANC-1 with NBMPR 
The results are inconsistent, especially for the 48-hour treatment. After 24 hours, the cell viabilities are very similar 
to one another, a trend that is not present after 48 hours. Common to the two graphs is that both indicate the results 
of an unsucessful inhibition of hENT1, since cell viability does not increase for cells treated with NBMPR. From left 
to right: Gem (black bar), 1 nM NBMPR + Gem, 10 nM NBMPR + Gem, 50 nM NBMPR + Gem and 100 nM 
NBMPR + Gem. The first group of bars represents cells treated with 10 µM Gem, the second 50 µM Gem and the 
third 100 µM Gem. 
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Figure 3. Co-treatment with Dilazep using Capan-1 cells. 
The results do not show difference between cells treated with Gemcitabine and cells treated with a combination of 
Gemcitabine and Dilazep. The cell viability is not changed for the cells with hENT1 inhibited, which indicates an 
unsuccessful inhibition. From left to right: Gemcitabine (black bar), 1 nM Dilazep + Gemcitabine, 10 nM Dilazep + 
Gemcitabine, 25 nM Dilazep + Gemcitabine and 50 nM Dilazep + Gemcitabine. The first group of bars represents 
cells treated with 10 µM Gemcitabine, the second 50 µM Gemcitabine and the third 100 µM Gemcitabine. 
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Figure 4. Co-treatment with NBMPR using Capan-1 cells. 
The results from the 24 hour-treatment show two significant differences; between cells treated with 50 µM Gem and cells 
treated with 1 nM NBMPR + 50 µM Gem as well as cells treated with 10 nM NBMPR + 50 µM Gem. These significant 
differences do not recur in the 48-hour treatment. From left to right: Gem (black bar), 1 nM NBMPR + Gem, 10 nM NBMPR 
+ Gem, 50 nM NBMPR + Gem and 100 nM NBMPR + Gem. The first group of bars represents cells treated with 10 µM 
Gem, the second 50 µM Gem and the third 100 µM Gem. 
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Pre-treatment 
 
The Pre-Treatment was initiated because of the inconclusive results from the Co-treatment. Here, the cells were 
incubated with the inhibitor before the cells were treated with a Co-Treatment. In other words, the cells were 
treated with the inhibitor before treated with a combination of the inhibitor and Gem. 2, 4 and 24 hours 
incubation time with inhibitor before a Co-Treatment were tested. This treatment was tested on Capan-1, since 
the treatments on BxPC-3 had not yet begun. 
 
2- and 4-hour Pre-Treatment were initially tested. The 2-hour Pre-Treatment incubation time shown in Figures 5 
and 6 show similar results as the Co-Treatment does. The cell viability measured for the cells treated with only 
Gem were very similar to the cell viability measured for the cells treated with a combination of inhibitor and 
Gem. Both NBMPR and DZ show this trend. Because these results were so similar to the Co-Treatment, we 
increased the concentrations for the inhibitor and increased the incubation times for the Pre-Treatment. Instead 
of nanomolar concentrations, we tried micro molar (0.5, 1, 5 and 10 µM) concentrations for both NBMPR and 
DZ. The incubation time for the Pre-Treatment was also increased to 4 and 24 hours before Co-Treatment.  
 
The results for the 4 hour Pre-Treatment can be seen in Figures 7 and 8. As with previous experiments, these 
also indicate that the inhibition does not work properly. Both for DZ and NBMPR, the inhibition is modest both 
after 24 and 48 hours. Again, the results show that Gem has an effect on the cells treated with Gem alone, as 
well as the cells treated with a combination of inhibitor and Gem. This result also shows that Gem has an effect 
on the cells, but that the inhibitor does not block uptake of Gem via hENT1.  
 
24 hour Pre-Treatment was also tested on BxPC-3, the results for which can be seen in Figures 9 and 10. These 
results are somewhat promising, since they show a trend of increasing cell viability with increasing inhibitor 
concentration. Important to bear in mind is that these results are pooled results from two experiments and the 
results from these two experiments differed from one another. This combined with the fact that the inhibition, 
although significant, still is poor laid the foundation for the decision to try a third inhibitor, DP.  
 
The results for Capan-1 can be seen in Figures 11 and 12, and does show a similar trend as the results from 
BxPC-3 did, although not as prominent. This, too, supported the decision to try DP.    
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Figure 5. A 2-hour Pre-Treatment with DZ followed by a 24- or 48-hour Co-Treatment using Capan-1.  
This data does not show an inhibited Gem uptake since the cell viability for the cells treated with Gem is not entirely 
different from the cell viability displayed by the cells treated with a combination of DZ and Gem. From left to right: Gem, 1 
nM DZ + Gem, 10 nM DZ + Gem, 25 nM DZ + Gem and 50 nM DZ + Gem. The first group of bars represents cells treated 
with 10 µM Gem, the second 50 µM Gem and the third 100 µM Gem. 
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Figure 6. A 2-hour Pre-Treatment with NBMPR followed by a 24- or 48-hour Co-Treatment using Capan-1.  
This data show a promising trend after 24 hours, a trend which is not present after 48 hours. The 48 hour result indicates 
hENT1 not being inhibited, since the cell viability for the cells treated with Gem does not differ from the cell viability 
displayed by the cells treated with a combination of NBMPR and Gem. From left to right: Gem, 1 nM NBMPR + Gem, 10 
nM NBMPR + Gem, 50 nM NBMPR + Gem and 100 nM NBMPR + Gem. The first group of bars represents cells treated 
with 10 µM Gem, the second 50 µM Gem and the third 100 µM Gem. 
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Figure 7. A 4-hour Pre-Treatment with DZ followed by a 24- or 48-hour Co-Treatment using Capan-1.  
This data does not show a decreased Gem uptake. The cell viability for the cells treated with Gem does not differ from the 
cell viability displayed by the cells treated with a combination of DZ and Gem, indicating that the treatments do not differ 
from one another. From left to right: Gem, 1 nM DZ + Gem, 10 nM DZ + Gem, 50 nM DZ + Gem and 100 nM DZ + Gem. 
The first group of bars represents cells treated with 10 µM Gem, the second 50 µM Gem and the third 100 µM Gem. 
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Figure 8. A 4-hour Pre-Treatment with NBMPR followed by a 24- or 48-hour Co-Treatment using Capan-1.  
This data does not show an inhibited Gem uptake since the cell viability for the cells treated with Gem is not higher than the 
cell viability displayed by the cells treated with a combination of NBMPR and Gem. This indicates a successful Gem uptake, 
and therefore an unsuccessful hENT1 inhibition.  From left to right: Gem, 1 nM NBMPR + Gem, 10 nM NBMPR + Gem, 50 
nM NBMPR + Gem and 100 nM NBMPR + Gem. The first group of bars represents cells treated with 10 µM Gem, the 
second 50 µM Gem and the third 100 µM Gem. 
 
37 
 
 
 
  
Figure 9. A 24-hour Pre-Treatment with DZ followed by a 24- or 48-hour Co-Treatment using BxPC-3.  
From left to right: Gem, 1 nM DZ + Gem, 10 nM DZ + Gem, 50 nM DZ + Gem and 100 nM DZ + Gem. The first group of 
bars represents cells treated with 10 µM Gem, the second 50 µM Gem and the third 100 µM Gem. This data does show an 
inhibited Gem uptake. The cell viability for the cells treated with Gem is ifferent from the cell viability displayed by the cells 
treated with a combination of DZ and Gem.  
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Figure 10. A 4-hour Pre-Treatment with NBMPR followed by a 24- or 48-hour Co-Treatment using BxPC-3.  
From left to right: Gem, 0.5 µM NBMPR + Gem, 1 µM NBMPR + Gem, 5 µM NBMPR + Gem and 10 µM NBMPR + Gem. 
The first group of bars represents cells treated with 10 µM Gem, the second 50 µM Gem and the third 100 µM Gem. This 
data does not show an inhibited Gem uptake since the cell viability for the cells treated with Gem is not significantly 
different from the cell viability displayed by the cells treated with a combination of NBMPR and Gem.  
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Figure 11. A 24-hour Pre-Treatment with DZ followed by a 24- or 48-hour Co-Treatment using Capan-1.  
From left to right: Gem, 0.5 µM DZ + Gem, 1 µM DZ + Gem, 5 µM DZ + Gem and 10 µM DZ + Gem. The first group of 
bars represents cells treated with 10 µM Gem, the second 50 µM Gem and the third 100 µM Gem. This data does to some 
extent show an inhibited Gem uptake. After 24 hour Co-Treatment (left graph), there is a trend showing increased cell 
viability with increasing DZ concentration. This trend is not present after 48 hour Co-Treatment. Important to note it that the 
results showed here are pooled from two separate experiments. Data from each of the experiments can be seen in table E, 
Appendix 2.  
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Figure 12. A 4-hour Pre-Treatment with NBMPR followed by a 24- or 48-hour Co-Treatment using Capan-1.  
From left to right: Gem, 0.5 µM NBMPR + Gem, 1 µM NBMPR + Gem, 5 µM NBMPR + Gem and 10 µM NBMPR + Gem. 
The first group of bars represents cells treated with 10 µM Gem, the second 50 µM Gem and the third 100 µM Gem. This 
data does not show an inhibited Gem uptake since the cell viability for the cells treated with Gem is not significantly 
different from the cell viability displayed by the cells treated with a combination of NBMPR and Gem, with the exception of 
the values in the left graph being significantly different from control (Gem only). This result is not visible after 48 hours.   
 
